Telix Pharmaceuticals Limited
ASX:TLX
$ 14.80
$-0.65 (-4.21%)
$ 14.80
$-0.65 (-4.21%)
End-of-day quote: 05/17/2024

Telix Pharmaceuticals financials at a glance

The revenue of Telix Pharmaceuticals is reported as 0.50255 billion Dollars in the fiscal year 2023. The earnings were 0.12 Dollars per share in 2023, which was 142.86 higher than 2022. And about 0.01422 billion Dollars are reported as free cash flow in the financials of Telix Pharmaceuticals 2023. No dividends were paid to the shareholders of the Telix Pharmaceuticals stock ASX:TLX in the financial year 2023.

$502.55M
Revenue
$0.12
Earnings Per Share
62.56%
Gross Margin %
$47.63M
Free Cash Flow
Revenue
502.55
Earnings Per Share
0.12
Gross Margin %
62.56
Free Cash Flow
47.63

Financials

Year Year TTM 2023 2022 2021 2020 2019 2018 2017
Rev. Revenue N/A $502.55M $160.10M $7.60M $5.21M $3.49M $0.20M $0.00M
GM % Gross Margin % 63.36% 62.56% 61.55% 66.46% 61.17% 27.03% 100.00% 0.00%
OM Operating Margin 6.12% 10.32% -45.71% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Earnings Per Share $-0.15 $0.12 $-0.28 $-0.29 $-0.17 $-0.12 $-0.07 $-0.05
Div. Dividends N/A $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
PR % Payout Ratio % 0 0.00% -0.00% -0.00% -0.00% -0.00% 0 0
Sha. Shares N/AM 323.96M 316.71M 308.2M 280.41M 253.44M 228.74M 197.44M
OCF Operating Cash Flow N/A $23.90M $-63.97M $-59.33M $1.96M $0.00M $0.00M $0.00M
FCF Free Cash Flow N/A $47.63M $-73.17M $-62.05M $1.71M $0.00M $0.00M $0.00M
FCFS Free Cash Flow Per Share $0.01 $0.04 $-0.25 $-0.21 $0.01 $-0.10 $-0.10 $-0.05